GENE ONLINE|News &
Opinion
Blog

2022-06-27| In-DepthSpecial

Roe Reversal May Cause Downstream Issues in Repurposing Mifepristone

by Reed Slater
Share To

The Supreme Court of the United State’s decision to end the constitutional right to abortions (Roe v. Wade) has garnered attention for one of America’s most common abortion-inducing drugs, mifepristone. The drug, originally FDA approved in 2000 for use inducing pregnancy termination, has shown promise in other treatment areas like cancer, hormonal diseases, and mental health disorders. However, because individual states determine abortion laws now, access to mifepristone may be restricted for research purposes even outside of pregnancy termination. 

 

Mifepristone’s Current Uses and Mechanisms of Action

 

The FDA approved mifepristone for two indications: early pregnancy termination in conjunction with misoprostol and the second came in 2012 to treat Cushing’s syndrome. 

It's free! Log in now to read

LATEST
The Golden Age of Medicine: Advancements in Novel Modalities and Therapeutic Areas
2024-11-01
Strengthening Biotech Ties: Highlights from the BioConnect Forum and Future Collaboration between Taiwan and Australia
2024-10-31
AusBiotech 2024 Opening Ceremony: From Local to Global – Shaping the Future of Life Sciences and Biotech in Australia
2024-10-30
AMS BioteQ Showcases Game-Changing Innovations at Medical Japan 2024
2024-10-29
AusBiotech 2024 to Highlight Global Areas of Interest, Current Trends, and Research Directives in Australia’s Diverse Biotech Industry
2024-10-25
BPIPO and DCB Collaborate with NVIDIA to Host AI Forum, Focusing on Cross-Domain Integration for Precision Health
2024-10-25
CDMO Samsung Bio Secures Record $1.24 Billion Biopharma Manufacturing Contract, Raising Total 2024 Deal Value to Over $3.3 Billion
2024-10-23
EVENT
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top